Agilent recasts segment financials moving cell analysis to diagnostics and genomics

AGILENT TECHNOLOGIES, INC.

Move of cell analysis from life sciences/applied markets to diagnostics/genomics segment effective Q1 FY2024.
Historical FY2023 data recast in Exhibit 99.1; three reportable segments unchanged.
No change to Agilent CrossLab segment; recast for comparability only.

item 8.01 item 9.01

AGILENT TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001090872-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.